CYP2C19 and major depressive disorder: An additional possibility is that in the Middle East the frequency of non-normal metaboliser phenotypes of CYP2C19 and CYP2D6 might be inferior to other ethnic groups around the world, reducing the overall spectrum of actionable genotypes for pharmacogenomic guided treatment in major depression.